Background. Hydroxychloroquine with or without azithromycin was one of the common therapies at the beginning of the COVID-19 pandemic. They can prolong QT interval, cause torsade de pointes, and lead to sudden cardiac death. We aimed to assess QT interval prolongation and its risk factors in patients who received hydroxychloroquine with or without azithromycin. Methods. This study was a retrospective cohort study. One hundred seventy-two confirmed COVID-19 patients were included in this study, hospitalized at Babol University of Medical Sciences hospitals between March 5, 2020, and April 3, 2020. Patients were divided into two groups: hydroxychloroquine alone and hydroxychloroquine with azithromycin. Electrocardiograms were used for outcome assessment. Results. 83.1% of patients received hydroxychloroquine plus azithromycin vs. 16.9% of patients who received only hydroxychloroquine. The mean age of patients was .The mean of posttreatment QTc interval in the monotherapy group was shorter than the mean of posttreatment QTc interval in the combination therapy group, but it had no significant statistical difference ( milliseconds vs. milliseconds; ). Generally, 22.1% of patients had a prolonged QTc interval after treatment. Male gender, or baseline milliseconds, or high-risk Tisdale score increased the likelihood of prolonged QTc interval. Due to QTc prolongation, fourteen patients did not continue therapy after four days. Conclusions. Hospitalized patients treated by hydroxychloroquine with or without azithromycin had no significant difference in prolongation of QT interval and outcome. The numbers of patients with prolonged QT intervals in this study emphasize careful cardiac monitoring during therapy, especially in high-risk patients.

中文翻译：

---

羟氯喹和阿奇霉素对 COVID-19 确诊患者 QT 间期延长和其他心律失常的影响

背景。羟氯喹加或不加阿奇霉素是 COVID-19 大流行开始时的常用疗法之一。它们可以延长 QT 间期，引起尖端扭转型室速，并导致心源性猝死。我们旨在评估接受羟氯喹联合或不联合阿奇霉素的患者的 QT 间期延长及其危险因素。方法。本研究为回顾性队列研究。本研究纳入了 172 名确诊的 COVID-19 患者，他们于2020 年 3 月 5 日至 2020 年4月 3 日期间在巴博尔医科大学医院住院. 患者分为两组：单独使用羟氯喹和使用羟氯喹联合阿奇霉素。心电图用于结果评估。结果。83.1% 的患者接受了羟氯喹联合阿奇霉素治疗，而仅接受羟氯喹治疗的患者比例为 16.9%。患者的平均年龄为. 单药组治疗后QTc间期均值短于联合治疗组治疗后QTc间期均值，但差异无统计学意义（毫秒对比毫秒；）。一般来说，22.1%的患者在治疗后QTc间期延长。男性或基线毫秒或高风险 Tisdale 评分增加了 QTc 间期延长的可能性。由于 QTc 延长，14 名患者在四天后没有继续治疗。结论。接受羟氯喹联合或不联合阿奇霉素治疗的住院患者在 QT 间期延长和结局方面没有显着差异。本研究中 QT 间期延长的患者数量强调在治疗期间进行仔细的心脏监测，尤其是在高危患者中。